US court rules against Teva on generic Viagra

By GLOBES
August 16, 2011 11:46

 
X

Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analyses from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user uxperience almost completely free of ads
  • Access to our Premium Section and our monthly magazine to learn Hebrew, Ivrit
  • Content from the award-winning Jerusalem Repor
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief

UPGRADE YOUR JPOST EXPERIENCE FOR 5$ PER MONTH Show me later Don't show it again

Teva Pharmaceutical Industries Ltd. on Tuesday lost a patent infringement case for generic Viagra brought by Pfizer Inc. The US District Court for the Eastern District of Virginia upheld Pfizer patents and banned Teva from marketing its generic version of the erectile dysfunction treatment until October 2019. The decision is subject to appeal.

Pfizer EVP and general counsel Amy Schulman said, "We are pleased that the court recognized the validity and enforceability of our Viagra patent for the treatment of erectile dysfunction. Protecting the intellectual property rights of our innovative core is critical, and Friday's court decision acknowledges Teva's clear violation of our patent rights."

Teva had planned to launch generic Viagra in 2012 and had already received preliminary approval from the US Food and Drug Administration (FDA).

Teva's share price fell 3.3 percent by late afternoon on the TASE on Tuesday to NIS 137.80, and was down 0.1% in premarket trading on Nasdaq to $39.70, giving a market of $35.4 billion.

Related Content

Breaking news
July 19, 2018
Three rockets launched from Gaza Strip into Israel

By JERUSALEM POST STAFF